FDA Reverses Broad Abilify Approval, Otsuka Says
The U.S. Food and Drug Administration has rescinded approval for an exclusivity-threatening use of Otsuka Pharmaceutical Co. Ltd.'s blockbuster Abilify but still intends to approve generic versions, the Japanese drugmaker told...To view the full article, register now.
Already a subscriber? Click here to view full article